Table 2 Clinical profiles of 19 patients with corticosteroid treatment

Patient no.	Age at onset	Sex	Obstructive jaundice	Abdominal pain	Pancreatic ductal change	Total bilirubin (m g/dl)	Alkaline phosphatase (IU/l)	IgG4 (mg/dl)	BT–PABA (%)	Initial dose of PSL (mg)	Cessation of CST (months after initiation)	Event during follow -up	Period to event occurence or observation period (months)
1	70	F	+	–	Diffuse	5.8	1643	133		40	–	IP	26
2	57	M	+	–	Diffuse	10.6	418			25	29	IP	45
3	75	M	+	–	Diffuse	6.7	1427	354		30	–	IP	15
4	63	M	+	+	Local	3.0	850	691	45	30	–	OJ	4
5	58	M	+	+	Local	9.2	2744			50	5	OJ	22
6	61	M	–	–	Local	0.4	740	410		40	–	OJ	27
7	69	F	–	+	Diffuse	0.4	996	249	54	40	–	None	72
8	66	M	+	+	Local	5.3	2299	525	75	40	–	None	56
9	55	M	+	+	Diffuse	1.7	222	320		40	–	None	53
10	66	M	–	+	Diffuse	0.5	113	310		30	–	None	54
11	73	M	+	+	Local	5.4	1041	360	50	30	–	None	49
12	72	F	+	–	Diffuse	1.6	1968	1400	44	30	–	None	36
13	61	M	+	+	Local	1.6	1290	578	63	30	–	None	27
14	58	M	+	–	Diffuse	6.9	1004	481		30	–	None	21
15	71	M	–	–	Local	0.6	420	470		30	–	None	15
16	55	M	+	–	Diffuse	2.9	728			30	–	None	13
17	61	M	–	+	Local	0.5	217	974	64	30	–	None	15
18	65	M	+	+	Local	5.4	481	1260		30	–	None	12
19	64	M	–	–	Diffuse	0.4	171	361	36	30	–	None	11

BT–PABA, N-benzoyl-l-tyrosyl-p-aminobenzoic acid test >70% normal; IP, interstitial pneumonia; OJ, obstructive jaundice caused by intrapancreatic bile duct stenosis; PSL, prednisolone. Normal range: Total bilirubin, 0.3–1.3 mg/dl; alkaline phosphatase, 60–201 IU/l; IgG4, <135 mg/dl.